GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Green Cross Corp (XKRX:006280) » Definitions » Research & Development

Green Cross (XKRX:006280) Research & Development : ₩166,475 Mil (TTM As of Mar. 2025)


View and export this data going back to 1989. Start your Free Trial

What is Green Cross Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Green Cross's Research & Development for the three months ended in Mar. 2025 was ₩36,566 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was ₩166,475 Mil.

Green Cross Research & Development Historical Data

The historical data trend for Green Cross's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Green Cross Research & Development Chart

Green Cross Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 137,987.00 146,030.00 191,347.00 173,487.00 166,198.00

Green Cross Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36,290.00 39,326.00 38,472.00 52,111.00 36,566.00

Green Cross Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩166,475 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Green Cross  (XKRX:006280) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Green Cross Research & Development Related Terms

Thank you for viewing the detailed overview of Green Cross's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Green Cross Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Green Cross Corp (XKRX:006280) » Definitions » Research & Development
Comparable Companies
XKRX:009420 XKRX:069620 XKRX:195940 XKRX:237690 XKRX:185750 XKRX:003090 XKRX:003850 XKRX:068760 XKRX:086450 XKRX:000640 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA
Traded in Other Exchanges
N/A
Address
303 Bojeong-Dong, Giheung-Gu, Yongin, Gyeonggi, KOR, 449-070
Website
http://www.greencross.com
Green Cross Corp is one of the global leaders in the healthcare sector. The Montreal-based biopharmaceutical company primarily develops intravenous immunoglobulin (IVIG), a key therapeutic solution for the treatment of patients with infectious and immune diseases, and albumin, used as a blood-volumizing agent and in the treatment of burns. Currently, the company has a global presence through its association with various subsidiaries.

Green Cross Headlines

No Headlines